glp-1 type 2 diabetes Receptor Agonists and Research to Treat Overeating and Substance Use Disorders GLP-1 receptor agonists | How

As a new Citigroup report (the source of the previous two graphics) notes, there are more than a hundred new GLP-1 drugs in the pipeline that aim to be more convenient (as pills rather than injections), reduce side effects like nausea and muscle loss, or simply provide better weight-loss results

Garvey on CagriSema and the Future of Obesity Care Timothy Garvey, MD, of the University of Alabama at Birmingham, reviews the latest data on CagriSema and emerging amylin-based therapies presented at the 2026 ADA Scientific Sessions

Effective treatment combines the right medication with ongoing education and support

Synthesis of (((ethane-1,2-diylbis(azanediyl))bis(carbonyl))bis(4,1-phenylene))diboronic acid(EBPBA) 4-Carboxyphenylboronic acid (3.65 g, 22.00 mmol), ethylenediamine dihydrochloride (1.33 g, 10.00 mmol), HATU (11.40 g, 30.00 mmol) and HOAT (4.08 g, 30.00 mmol) were dissolved in DMF (40 mL) under nitrogen atmosphere and ice bath conditions